Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20
BW Businessworld

Glenmark Pharmaceuticals and Menarini enter into exclusive licensing agreement for commercializing Ryaltris™ nasal spray across numerous markets throughout Europe

Glenmark Pharmaceuticals and Menarini enter into exclusive licensing agreement for commercializing Ryaltris™ nasal spray across numerous markets throughout Europe

Photo Credit :

Mumbai (Maharashtra) [India] December 23 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty SA, has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercializing its innovative nasal spray Ryaltris™ across 33 countries in Europe, including the Balkan region.
Ryaltris™ [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.
Under the terms of the agreement, Glenmark will be responsible for the continued development and regulatory approval of Ryaltris™ in these markets.
Menarini will be responsible for the scientific information and the commercialization of Ryaltris™ in those markets, following regulatory approval.
Glenmark will receive an upfront payment as well as launch & sales-based milestone payments from Menarini for Ryaltris™ sales.
"We are excited to partner with Menarini for Ryaltris™ across Europe as they have a proven track record in partnering and commercialising respiratory products in the region. This partnership is another step in establishing Glenmark's respiratory focus in Europe. While Glenmark will launch Ryaltris™ through its own front ends in some markets, this arrangement will allow the product to compete across Europe. This is also aligned with our vision to make Ryaltris™ the first global brand of Glenmark by launching it in several markets across the world," said Achin Gupta, Executive Vice President, Business Head EMEA-L (Europe, Middle East, Africa, Latam) Glenmark Pharmaceuticals.
"We are delighted to have undertaken this exclusive licensing agreement with Glenmark Pharmaceuticals. Ryaltris™ is a perfect addition to our European respiratory and allergy portfolio and we can count on our established experience in the relevant therapeutic area to bring this novel option to patients. We look forward to receiving Ryaltris™ registration and being able to launch operations as soon as practicable," commented Pio Mei, General Manager Menarini Group.
Ryaltris™ (olopatadine hydrochloride and mometasone furoate) nasal spray, the company's respiratory pipeline asset is partnered with Hikma Pharmaceuticals PLC for the commercialisation in the US market. Ryaltris™ sales continue to progress well in Australia, after the successful launch earlier this year by Glenmark's partner, Seqirus Pty Ltd.
Ryaltris™ was also recently launched in South Africa. Glenmark plans to initiate commercial launch in Ukraine and Uzbekistan in the next few months. Glenmark is supporting its partner Yuhan Corporation to launch Ryaltris™ by the end of the March 2021 in South Korea.
Glenmark has received approval for Ryaltris™ in Australia, South Korea, Cambodia, Ukraine, Uzbekistan, Namibia and South Africa. The company had already filed an application for Ryaltris™ approval in the European Union, Canada, Russia, Brazil, Malaysia, Saudi Arabia and several other markets. Glenmark's partner in China, Grand Pharmaceutical (China) Co Ltd, plans to submit an IND in this financial year.
This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

Disclaimer: The views expressed in the article above are those of the authors' and do not necessarily represent or reflect the views of this publishing house. Unless otherwise noted, the author is writing in his/her personal capacity. They are not intended and should not be thought to represent official ideas, attitudes, or policies of any agency or institution.


ANI

ANI

More From The Author >>